Executive summary
US Patent 10,022,440 claims combination immunotherapy for Type 1 diabetes by administering a pro-inflammatory adjuvant (CpG-ODN and/or Freund’s/MDP) together with an anti-inflammatory adjuvant (hemoglobin:haptoglobin, hemin, heme:hemopexin, ethyl pyruvate, ATG, and/or anti-CD3) plus a target autoantigen (insulin, proinsulin, insulin B chain, GAD, IA-2). The claims are broad in the choice of adjuvants, include timing (simultaneous or sequential), and add optional immune-cell migration modulators (GM-CSF/G-CSF).
From a landscape standpoint, the estate sits at the intersection of (i) CpG and other TLR9/TLR agonist adjuvants, (ii) antigen-specific immunotherapy for T1D (GAD65, insulin/proinsulin, IA-2, insulin B chain), and (iii) immune-regulatory “anti-inflammatory” modulators including heme/hemoglobin axis products, ethyl pyruvate, and clinically used immunosuppressive antibodies (ATG, anti-CD3). These are crowded technology areas with many earlier, overlapping publications and patents on antigen plus adjuvant, and on the individual anti-inflammatory agents. The key novelty risk is whether the specific combination and stated adjuvant menu were non-obvious relative to prior disclosures that used antigen plus CpG and/or used the anti-inflammatory agents in immune modulation contexts relevant to autoimmune disease or T1D.
US Patent 10,022,440 claims and patent landscape for inducing protective immunity against Type 1 diabetes autoantigens
What does US 10,022,440 claim: pro-inflammatory plus anti-inflammatory adjuvant combination for T1D autoantigens?
Plain-English claim core
US 10,022,440 claims a method of inducing a protective immune response against T1D autoantigens by co-administering:
-
A target autoantigen chosen from:
- insulin
- proinsulin
- insulin B chain
- GAD
- IA-2
-
A pro-inflammatory adjuvant selected from one or more:
- CpG oligonucleotide sequences (CpG-ODN)
- CpG rich oligonucleotides
- incomplete Freund’s adjuvant (IFA)
- complete Freund’s adjuvant (CFA)
- Freund’s adjuvant with muramyldipeptide (MDP)
-
An anti-inflammatory adjuvant selected from one or more:
- hemoglobin:haptoglobin
- hemin
- heme:hemopexin
- ethyl pyruvate (EP)
- anti Thymocyte Globulin (ATG)
- anti-CD3
Timing variants are explicitly claimed:
- Anti-inflammatory adjuvant after pro-inflammatory adjuvant (Claim 3)
- Pro-inflammatory and anti-inflammatory adjuvants simultaneously (Claim 4)
Optional immune migration module (Claims 5-6):
- immuno-modulating molecule inducing immune cell migration
- selected from GM-CSF and/or G-CSF
Claim-by-claim compression (1–6)
| Claim |
What is being protected (high-level) |
Constraint strength |
| 1 |
Antigen-specific “protective immune response” method using (CpG/IFA/CFA/MDP) + (hemoglobin:haptoglobin/hemin/heme:hemopexin/EP/ATG/anti-CD3) + insulin/proinsulin/GAD/IA-2/insulin B chain |
Broad across adjuvant species; novelty hinges on the specific pairing concept and use in T1D autoantigen context |
| 2 |
Narrows anti-inflammatory adjuvant menu to hemoglobin:haptoglobin, hemin, EP |
Medium narrowing; may still be anticipated by earlier EP/hemoglobin-hemin hemoprotein immunomodulation paired with antigen |
| 3 |
Anti-inflammatory after pro-inflammatory |
Timing constraint can narrow against prior art that uses same-time dosing, reverse dosing, or separate phases |
| 4 |
Simultaneous administration |
Timing constraint; overlaps with “adjuvant co-administration” art for antigen vaccines |
| 5 |
Adds immuno-modulating molecule inducing immune cell migration |
Optional add-on; likely adds dependently-claimed breadth without strong limitation unless prior art uses GM-CSF/G-CSF in the exact setting |
| 6 |
GM-CSF and/or G-CSF |
Narrower optional layer; depends on whether migration modulators are already common with antigen-specific immunotherapy or tolerization schemes |
What patents protect the same concept: CpG plus antigen-specific immunotherapy for Type 1 diabetes?
Featured-snippet answer
The landscape for US 10,022,440 is dominated by prior intellectual property and academic disclosures covering Type 1 diabetes antigen administration (insulin/GAD/IA-2) combined with immunostimulatory adjuvants including CpG oligonucleotides and other pro-inflammatory stimulators. Those references put pressure on novelty for Claim 1’s pro-inflammatory component.
Pro-inflammatory adjuvant cluster most relevant to claim language
- CpG-ODN / CpG rich oligonucleotides: patent families on TLR9 agonism, Th1-biased immunomodulation, and vaccine adjuvant uses.
- Freund’s adjuvant variants (CFA/IFA): longstanding immunology IP on boosting antigen responses.
- Freund’s with MDP: MDP is a known innate immune agonist (NOD2-related) and appears in adjuvant compositions in multiple immune therapy patent filings.
Critical analysis
Even if CpG combined with autoantigen-specific approaches in T1D is not identical to “protective immune response” framing, examiners and courts evaluate functional overlap: antigen-specific immune activation plus modulation of cytokine milieu. If earlier art teaches that CpG can enhance immunity to T1D antigens (or autoimmune antigen epitopes), the remaining differentiation in Claim 1 likely becomes the simultaneous or sequential inclusion of anti-inflammatory adjuvants that are typically associated with dampening autoreactivity rather than boosting immunogenicity.
What patents protect the anti-inflammatory adjuvants listed in US 10,022,440 for autoimmune modulation?
Featured-snippet answer
US 10,022,440’s anti-inflammatory menu (hemoglobin:haptoglobin, hemin, heme:hemopexin, ethyl pyruvate, ATG, anti-CD3) overlaps with multiple patentable and non-patent literatures on (i) heme-scavenging and anti-oxidant immune regulation, and (ii) immunosuppressive antibody therapy targeting T cells.
Hemoglobin/haptoglobin, hemin, heme:hemopexin
- These are tied to heme biology and oxidative stress control, commonly associated with inflammatory modulation.
- Patent risk: individual compositions and uses in inflammatory/autoimmune contexts are often disclosed independently of CpG-based antigen vaccination concepts.
Ethyl pyruvate (EP)
- EP is widely disclosed in inflammatory disease contexts and as an immunomodulator.
- Patent risk: EP’s use to shift immune responses can predate the “pro-inflammatory + anti-inflammatory adjuvant” pairing described in Claim 1.
ATG and anti-CD3
- These are established immunotherapy agents:
- Anti-CD3 (e.g., teplizumab-like mechanisms) is specifically relevant to T1D treatment paradigms.
- ATG is established for transplant and autoimmune uses, including T1D-related immune suppression protocols.
Critical analysis
Claims that list ATG and anti-CD3 expand enforceability across antibody-administering practices. But prior art risk is also high: anti-CD3 and ATG have been used in T1D immune intervention strategies for years. The question becomes whether any prior patent teaches them as part of an antigen-specific regimen that also includes CpG or Freund’s/MDP pro-inflammatory adjuvants.
When does exclusivity for US Patent 10,022,440 end in the US, and what drives earlier loss?
Featured-snippet answer
For a US non-biosimilar drug method patent, exclusivity is driven by patent term (including any PTA) and potential terminal disclaimers. Your launch or licensing risk does not rely on “Orange Book exclusivity” unless the patent is listed for a specific FDA-approved product.
What determines the end date conceptually
- Earliest expiration = statutory term from earliest effective filing date (often ~20 years from earliest non-provisional filing, adjusted by PTA if applicable).
- Terminal disclaimer can cap effective term.
- If the patent is listed in FDA’s Orange Book for a drug product, that can affect regulatory exclusivity discussions, but method patents typically do not create “exclusivity” in the Orange Book sense; they constrain infringement.
Critical analysis
Because your claims are method-level and combination-adjuvant based, the practical exclusivity period is determined by whether competitors can design around the specific adjuvant combinations and timing, not by Orange Book status.
How strong is the patent estate for this mechanism: is Claim 1’s breadth likely to survive obviousness attacks?
Featured-snippet answer
Claim 1 is broad across both adjuvant classes and specific antigen choices. That breadth increases vulnerability to an obviousness argument built from multiple prior references: one for CpG/Freund’s/MDP as antigen immunostimulants, and separate references for anti-inflammatory immunomodulators (EP/hemoprotein axis/ATG/anti-CD3) used to regulate autoimmune immunity.
Likely obviousness attack structure
- Reference set A: Antigen-specific immunotherapy for T1D with CpG (or Freund’s) to enhance immune response.
- Reference set B: EP or heme-scavenging or heme-binding proteins used to dampen inflammatory responses in immune-mediated disease.
- Reference set C: Anti-CD3 or ATG used to modulate T-cell responses in T1D or analogous autoimmune contexts.
- Combination argument: A skilled person would expect that adding a counter-regulatory agent improves safety or shifts the immune outcome while maintaining antigen-driven immunity.
Countervailing strength in Claim 1
- The claim requires both pro-inflammatory and anti-inflammatory adjuvants in the same method and links to protective immune response against T1D autoantigens.
- If the specification supports a non-additive immune outcome (not merely additive suppression), that can help.
- Timing claims (Claims 3-4) create additional constraints but likely still remain obvious variants if both co-administration and sequential dosing were known.
Risk-weighted view
- Claim 1: high prior art exposure across both adjuvant categories; strongest defense typically depends on experimental evidence in the specification showing a synergistic protective outcome.
- Claims 2-6: narrower, but still vulnerable because the anti-inflammatory menu items (EP, hemin, Hb:haptoglobin) and immune migration factors (GM-CSF/G-CSF) are individually disclosed in immunomodulation contexts.
What generic entry risks exist for methods like this: what would a design-around require?
Featured-snippet answer
Design-arounds target the adjuvant pairing and timing, plus the autoantigen set and the optional migration modulators.
Likely design-around vectors
- Replace CpG/Freund’s/MDP pro-inflammatory adjuvants with an alternative innate agonist not covered by the claim (if not captured by “pro-inflammatory adjuvant comprises one or more of the following”).
- Replace the anti-inflammatory adjuvant with an agent not in the enumerated list.
- Change timing such that it is neither “after” nor “simultaneously” as implemented, depending on how infringement is construed for method steps.
- Use different autoantigens not listed (though the claim list includes major canonical T1D autoantigens; design-away may be difficult commercially).
- Omit GM-CSF/G-CSF if relying on Claims 5-6.
Critical analysis
Because the pro-inflammatory and anti-inflammatory adjuvants are enumerated but still broad in number, a competitor can attempt to keep the therapeutic concept while swapping adjuvant class members. The biggest infringement risk is if a competitor uses CpG together with EP or anti-CD3/ATG while giving insulin/GAD/IA-2.
Which companies are most likely to challenge or license around US 10,022,440 given the anti-CD3 and CpG adjacency?
Featured-snippet answer
The claim touches:
- Anti-CD3 immunotherapy companies and programs for T1D immune modulation.
- CpG adjuvant developers and vaccine-adjuvant platforms.
- Antigen-specific T1D immunotherapy developers.
Even without listing specific case captions here, the competitive pattern is clear: any entity running antigen-specific T1D immunotherapy with CpG or other TLR agonists plus an immunomodulatory counteragent faces potential exposure.
Competitive adjacency map (conceptual)
- T1D antigen-specific immunotherapy portfolios (GAD/insulin/proinsulin/IA-2)
- Immunotherapy regimens using anti-CD3 or ATG
- Adjuvant-driven vaccine platforms where CpG is a core technology
What FDA regulatory status matters for infringement, not just exclusivity?
Featured-snippet answer
FDA approval pathway affects product marketing timelines, but method patent infringement depends on whether the administered regimen matches the claim elements (autoantigen + specific adjuvant pairing and optional migration modulators).
Key infringement-relevant regulatory elements
- Evidence that an approved regimen actually uses CpG or Freund’s/MDP as the pro-inflammatory adjuvant
- Evidence that the regimen uses EP or heme-scavenging agents or anti-CD3/ATG as the anti-inflammatory adjuvant
- Evidence on dosing sequence (simultaneous vs after)
- Evidence on whether GM-CSF/G-CSF is included to induce immune migration
What patent litigation affects US 10,022,440, and how would it change market behavior?
Featured-snippet answer
Litigation status is a driver of licensing and launch timing. The claims’ broad adjuvant enumerations increase the chance that any competing antigen-adjuvant combination will be within the claim’s literal scope.
Critical analysis
In practice, parties may settle because:
- Proving non-infringement is harder with broad “comprises one or more” language.
- Obviousness and anticipation attacks can be built from standard immunology patent literature across both pro- and anti-inflammatory domains.
Key takeaways
- US 10,022,440 Claim 1 broadly covers Type 1 diabetes antigen immunotherapy using (CpG/Freund’s/MDP) as the pro-inflammatory adjuvant plus a selected anti-inflammatory adjuvant (hemoglobin:haptoglobin, hemin, heme:hemopexin, ethyl pyruvate, ATG, anti-CD3), with antigen restricted to insulin/proinsulin/insulin B chain/GAD/IA-2.
- The estate is highly vulnerable to obviousness constructed from prior art that separately teaches (i) CpG/Freund’s/MDP antigen immunostimulation and (ii) EP/heme-scavenging or ATG/anti-CD3 immune regulation in autoimmune disease.
- Timing claims (after vs simultaneous) narrow but may still be obvious if both administration modes are standard for combining adjuvants and immune modulators.
- Design-arounds most likely require changing at least one of: (a) the enumerated pro-inflammatory adjuvant, (b) the enumerated anti-inflammatory adjuvant, (c) the implemented timing of steps, or (d) the optional addition of GM-CSF/G-CSF.
- Competitive exposure is highest for programs combining T1D autoantigen vaccines with CpG (or other covered pro-inflammatory adjuvants) while also using EP/heme-scavenging agents or anti-CD3/ATG.
FAQs
1) Does US 10,022,440 cover antigen-specific tolerization (inducing tolerance) or only “protective immunity”?
The claims are framed as inducing a protective immune response; infringement analysis turns on whether the regimen and resulting immune effect align with the claimed method as construed.
2) If a competitor uses CpG plus ethyl pyruvate but omits anti-inflammatory antibodies, is it still within Claim 1?
If ethyl pyruvate is administered as the anti-inflammatory adjuvant and the regimen includes one of the specified autoantigens with a specified pro-inflammatory adjuvant, it fits the Claim 1 structure.
3) How do Claims 3 and 4 affect infringement risk for different dosing schedules?
They capture two specific patterns: anti-inflammatory adjuvant administered after pro-inflammatory or simultaneously. A materially different dosing sequence can be a design-around depending on claim construction.
4) Are GM-CSF/G-CSF required for infringement of Claim 1?
No. Claims 5-6 are dependent; GM-CSF/G-CSF are only implicated if they are used in the additional migration-inducing step as claimed.
5) Can switching from GAD/IA-2/insulin variants to other T1D antigens avoid the patent?
The autoantigen is restricted to the enumerated list in Claim 1, so using antigens outside that list is a potential design-around, assuming the regimen does not still infringe through equivalency theories.
References
- United States Patent 10,022,440. (Claims provided in prompt).
